Potential Diagnostic and Prognostic Value of microRNAs for the Patients of Acute Coronary Syndrome
This trial is active, not recruiting.
|Condition||acute coronary syndrome|
|Sponsor||Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|
|Start date||April 2016|
|End date||December 2018|
|Trial size||100 participants|
|Trial identifier||NCT02755207, XH-16-003|
The purpose of this study is to evaluate the potential diagnostic and prognosis value of circulating microRNAs compared with cTnI for suspected ACS patients at the emergency department (ED) and intensive care unit (ICU).
Patients admitted to the hospital with the diagnosis of ACS
Patients admitted to the hospital without the diagnosis of ACS
Evaluate the diagnostic value of microRNAs in qPCR，in ACS
time frame: Day 7
Evaluate the prognostic value of microRNAs in ACS
time frame: 6 months
Male or female participants of any age.
Inclusion Criteria: Suspected ACS patients (STEMI, NSTEMI, and UA): Symptoms: Chest pain; angina pectoris; radiation pain; ECG: ST segment elevation or depression > 0.1 mV in at least 2 contiguous electrocardiographic leads or Pathological Q wave occurs; Cardiac ultrasound: Decreased cardiac function; History of coronary heart disease; Age>18 years; Informed consent. Exclusion Criteria: Patients who will undergo immediate PCI; Pregnant and lactating women; Patients with mental disorders; Patients are using other experimental drugs; Refusal to provide informed.
|Official title||Potential Diagnostic and Prognostic Value of microRNAs for the Patients of Acute Coronary Syndrome|
|Description||The present study is a single-center, prospective diagnostic study among patients presenting to the ED or ICU within 24 h of onset of chest pain suggestive of suspected ACS. We propose to construct the biobank of ACS and evaluate the potential diagnostic value of circulating microRNAs compared with cTnI for suspected ACS patients. All the patients are to be followed up for 6 months. Final diagnosis was made by an expert panel cardiologist, based on all available clinical information including cTnI measurements, ECG, coronary angiography, cardiac exercise tests and information from hospital discharge letters. The concentrations of microRNAs will be evaluated by quantitative reverse transcription PCR, using highly specific primers and hybridization probes.|
Call for more information